Nicolas G.
- Country
- France
- Department
- Pneumology
Research Overview
- Dose-Escalation Study of Zongertinib in Patients with Advanced Non-Small Cell Lung Cancer and Solid Tumors with HER2 Aberrations
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
- Phase I Study of BAY2927088 in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR and/or HER2 Mutations
Data & Insights
Has run more than one trial at 483 of 756 partner sites.
Specializations
Primary Lung Cancer Focus
The investigator specializes in treating various forms of non-small cell lung cancer (NSCLC), with particular emphasis on advanced and metastatic disease states. Their expertise extends to managing cases with specific genetic mutations, including EGFR mutations and HER2 mutations.
- Advanced NSCLC
- Early-stage Non-squamous NSCLC
- Extensive-stage Small Cell Lung Cancer
Molecular Targeted Therapy
The investigator focuses on innovative therapeutic approaches targeting specific molecular pathways in lung cancer. Their work involves bispecific antibodies and novel combinations of immunotherapy agents with conventional treatments.
- EGFR-targeted Therapies
- c-Met Targeting Approaches
- Antibody-Drug Conjugates
Additional Therapeutic Areas
Beyond lung cancer, the investigator's expertise extends to treating thymic carcinoma and B-cell malignancies. Their research encompasses both early-stage disease management and advanced treatment protocols.
- Metastatic Thymic Carcinoma
- B3-thymoma
- Perioperative Therapy
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.